These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38742595)

  • 1. A unified Bayesian framework for bias adjustment in multiple comparisons from clinical trials.
    Du Y; Li J; Raha S; Qu Y
    Stat Med; 2024 Jul; 43(15):2928-2943. PubMed ID: 38742595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model averaging for treatment effect estimation in subgroups.
    Bornkamp B; Ohlssen D; Magnusson BP; Schmidli H
    Pharm Stat; 2017 Mar; 16(2):133-142. PubMed ID: 27935199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semi-parametric Bayesian regression for subgroup analysis in clinical trials.
    Gamalo-Siebers M; Tiwari R
    J Biopharm Stat; 2019; 29(6):1024-1042. PubMed ID: 30747568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporating prior beliefs about selection bias into the analysis of randomized trials with missing outcomes.
    Scharfstein DO; Daniels MJ; Robins JM
    Biostatistics; 2003 Oct; 4(4):495-512. PubMed ID: 14557107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simulation-based adjustment after exploratory biomarker subgroup selection in phase II.
    Götte H; Kirchner M; Sailer MO; Kieser M
    Stat Med; 2017 Jul; 36(15):2378-2390. PubMed ID: 28436046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation in multi-arm two-stage trials with treatment selection and time-to-event endpoint.
    Brückner M; Titman A; Jaki T
    Stat Med; 2017 Sep; 36(20):3137-3153. PubMed ID: 28612371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection.
    Carreras M; Brannath W
    Stat Med; 2013 May; 32(10):1677-90. PubMed ID: 22744936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporating data from various trial designs into a mixed treatment comparison model.
    Schmitz S; Adams R; Walsh C
    Stat Med; 2013 Jul; 32(17):2935-49. PubMed ID: 23440610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing treatment effect heterogeneity in the presence of missing effect modifier data in cluster-randomized trials.
    Blette BS; Halpern SD; Li F; Harhay MO
    Stat Methods Med Res; 2024 May; 33(5):909-927. PubMed ID: 38567439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian approach to subgroup identification.
    Berger JO; Wang X; Shen L
    J Biopharm Stat; 2014; 24(1):110-29. PubMed ID: 24392981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian missing data framework for generalized multiple outcome mixed treatment comparisons.
    Hong H; Chu H; Zhang J; Carlin BP
    Res Synth Methods; 2016 Mar; 7(1):6-22. PubMed ID: 26536149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials.
    Collier W; Haaland B; Inker LA; Heerspink HJL; Greene T
    BMC Med Res Methodol; 2024 Feb; 24(1):39. PubMed ID: 38365599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian approach to noninferiority trials for proportions.
    Gamalo MA; Wu R; Tiwari RC
    J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using horseshoe prior for incorporating multiple historical control data in randomized controlled trials.
    Ohigashi T; Maruo K; Sozu T; Gosho M
    Stat Methods Med Res; 2022 Jul; 31(7):1392-1404. PubMed ID: 35379046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empirical shrinkage estimator for consistency assessment of treatment effects in multi-regional clinical trials.
    Quan H; Li M; Shih WJ; Ouyang SP; Chen J; Zhang J; Zhao PL
    Stat Med; 2013 May; 32(10):1691-706. PubMed ID: 22855311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian model selection techniques as decision support for shaping a statistical analysis plan of a clinical trial: an example from a vertigo phase III study with longitudinal count data as primary endpoint.
    Adrion C; Mansmann U
    BMC Med Res Methodol; 2012 Sep; 12():137. PubMed ID: 22962944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian approach to estimating causal vaccine effects on binary post-infection outcomes.
    Zhou J; Chu H; Hudgens MG; Halloran ME
    Stat Med; 2016 Jan; 35(1):53-64. PubMed ID: 26194767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis.
    Janjua S; Mathioudakis AG; Fortescue R; Walker RA; Sharif S; Threapleton CJ; Dias S
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013198. PubMed ID: 33448349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.